Pacira BioSciences, Inc.
PCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $179,516 | $181,099 | $168,923 | $187,253 |
| % Growth | -0.9% | 7.2% | -9.8% | – |
| Cost of Goods Sold | $34,278 | $40,866 | $34,306 | $39,886 |
| Gross Profit | $145,238 | $140,233 | $134,617 | $147,367 |
| % Margin | 80.9% | 77.4% | 79.7% | 78.7% |
| R&D Expenses | $25,966 | $28,200 | $25,342 | $23,897 |
| G&A Expenses | $33,326 | $37,614 | $31,205 | $29,272 |
| SG&A Expenses | $91,797 | $88,578 | $86,776 | $79,614 |
| Sales & Mktg Exp. | $58,471 | $50,964 | $55,571 | $50,342 |
| Other Operating Expenses | $21,113 | $14,956 | $20,509 | $19,152 |
| Operating Expenses | $138,876 | $131,734 | $132,627 | $122,663 |
| Operating Income | $6,362 | $8,499 | $1,990 | $24,704 |
| % Margin | 3.5% | 4.7% | 1.2% | 13.2% |
| Other Income/Exp. Net | $3,162 | -$10,426 | $6,716 | $822 |
| Pre-Tax Income | $9,524 | -$1,927 | $8,706 | $25,526 |
| Tax Expense | $4,092 | $2,920 | $3,894 | $9,485 |
| Net Income | $5,432 | -$4,847 | $4,812 | $16,041 |
| % Margin | 3% | -2.7% | 2.8% | 8.6% |
| EPS | 0.12 | -0.11 | 0.1 | 0.35 |
| % Growth | 209.1% | -210% | -71.4% | – |
| EPS Diluted | 0.12 | -0.11 | 0.1 | 0.34 |
| Weighted Avg Shares Out | 44,038 | 45,459 | 46,275 | 46,171 |
| Weighted Avg Shares Out Dil | 44,459 | 45,459 | 46,526 | 49,036 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,534 | $5,008 | $6,895 | $5,555 |
| Interest Expense | $3,653 | $4,695 | $4,580 | $3,834 |
| Depreciation & Amortization | $21,191 | $27,322 | $21,168 | $21,243 |
| EBITDA | $34,368 | $29,241 | $33,609 | $50,603 |
| % Margin | 19.1% | 16.1% | 19.9% | 27% |